Overview

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Status:
Completed
Trial end date:
2021-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of MND-2119 at a dose of 2g/day or 4g/day for 52 weeks in patients with hypertriglyceridemia.
Phase:
Phase 3
Details
Lead Sponsor:
Mochida Pharmaceutical Company, Ltd.